Stock Scorecard



Stock Summary for CytomX Therapeutics Inc (CTMX) - $2.19 as of 3/27/2024 10:15:25 PM EST

Total Score

10 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CTMX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CTMX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CTMX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for CTMX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for CTMX

Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Oracle ( NYSE:ORCL ) 3/12/2024 12:11:00 PM
CytomX Therapeutics ( CTMX ) Lags Q4 Earnings Estimates 3/11/2024 9:20:00 PM
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update - CytomX Therapeutics ( NASDAQ:CTMX ) 3/11/2024 8:10:00 PM
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update 3/11/2024 8:10:00 PM
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO ) 3/5/2024 1:00:00 PM
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate ( ADC ) Toolkit - Akari Therapeutics ( NASDAQ:AKTX ) , Peak Bio ( OTC:PKBO ) 3/5/2024 1:00:00 PM
Longtime Gilead Commercial Executive Joins IntegriChain as Chairman of the Board 2/28/2024 3:00:00 PM
CytomX ( CTMX ) to Report Q4 Earnings: Here's What to Expect 2/27/2024 4:52:00 PM
AstraZeneca's ( AZN ) sBLA for Enhertu Gets FDA's Priority Tag 1/30/2024 12:44:00 PM
Apellis ( APLS ) Down on Negative CHMP Opinion for Pegcetacoplan 1/29/2024 1:48:00 PM

Financial Details for CTMX

Company Overview

Ticker CTMX
Company Name CytomX Therapeutics Inc
Country USA
Description CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/7/2024

Stock Price History

Last Day Price 2.19
Last Day Price Updated 3/27/2024 10:15:25 PM EST
Last Day Volume 590,298
Average Daily Volume 1,399,962
52-Week High 2.85
52-Week Low 1.04
Last Price to 52 Week Low 110.58%

Valuation Measures

Trailing PE N/A
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -18.93
Free Cash Flow Ratio 0.85
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 1.17
Total Cash Per Share 2.59
Book Value Per Share Most Recent Quarter -0.70
Price to Book Ratio 5.04
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 1.46
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 67,722,000
Market Capitalization 148,311,180
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 99.43%
Reported EPS 12 Trailing Months -0.01
Reported EPS Past Year -0.02
Reported EPS Prior Year -1.52
Net Income Twelve Trailing Months -569,000
Net Income Past Year -569,000
Net Income Prior Year -99,317,000
Quarterly Revenue Growth YOY 32.20%
5-Year Revenue Growth 11.21%

Balance Sheet

Total Cash Most Recent Quarter 175,364,000
Total Cash Past Year 175,364,000
Total Cash Prior Year 95,574,000
Net Cash Position Most Recent Quarter 175,364,000
Net Cash Position Past Year 175,364,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -47,447,000
Total Stockholder Equity Prior Year -85,751,000
Total Stockholder Equity Most Recent Quarter -47,447,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.07
MACD Signal 0.11
20-Day Bollinger Lower Band 0.94
20-Day Bollinger Middle Band 1.70
20-Day Bollinger Upper Band 2.46
Beta 1.01
RSI 51.50
50-Day SMA 1.59
200-Day SMA 4.05

System

Modified 3/27/2024 10:15:26 PM EST